Seres Therapeutics (MCRB) Non Operating Interest Expenses (2020 - 2024)

Seres Therapeutics has disclosed Non Operating Interest Expenses across 5 years of filings, most recently posting $618000.0 for Q1 2024.

• In Q1 2024, Non Operating Interest Expenses fell 68.28% year-over-year to $618000.0; the TTM figure through Dec 2024 stood at $618000.0 (down 87.96% YoY), while the FY2023 annual figure was $2.5 million, down 59.0% from the prior year.
• Non Operating Interest Expenses came in at $618000.0 for Q1 2024 at Seres Therapeutics, down from $3.2 million in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $3.2 million in Q2 2023 to a low of $618000.0 in Q1 2024.
• Average Non Operating Interest Expenses over 5 years is $1.2 million, with a median of $744000.0 recorded in 2021.
• Year-over-year, Non Operating Interest Expenses jumped 154.74% in 2022 and tumbled 68.28% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at $759000.0 in 2020, then dropped by 2.77% to $738000.0 in 2021, then jumped by 154.74% to $1.9 million in 2022, then jumped by 69.52% to $3.2 million in 2023, then tumbled by 80.61% to $618000.0 in 2024.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $618000.0 in Q1 2024, $3.2 million in Q2 2023, and $1.9 million in Q1 2023.